NCT00400660View on ClinicalTrials.gov

A First Time In Human Study To Assess The Compound GSK615915

PHASE1CompletedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

November 23, 2005

Primary Completion Date

July 3, 2006

Study Completion Date

July 3, 2006

Conditions

Bronchospasm

Interventions

DRUG

GSK615915A

GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

DRUG

Placebo

Subjects will also receive placebo inhaler.

Trial Locations (1)

EH14 4AP

GSK Investigational Site, Edinburgh

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY